Iovance Biotherapeutics, Inc. IOVA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s accounts payable?
- Iovance Biotherapeutics, Inc. (IOVA) reported accounts payable of $37.45M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s accounts payable changed year-over-year?
- Iovance Biotherapeutics, Inc.'s accounts payable increased by 31.5% year-over-year, from $28.49M to $37.45M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s accounts payable has grown at a 10.4% compound annual growth rate (CAGR), from $13.51M to $22.16M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.